Abstract
Introduction: Primary subclavian vein thrombosis (PSVT) is a rare (2/100,000 per year) disorder, affecting mostly young, active and otherwise healthy individuals. Untreated it can lead to post thrombotic syndrome (PTS) which leaves the patient with a chronic impairment of the arm. Several treatment strategies have been suggested to avoid PTS: immediate thrombolysis and decompressive surgery, delayed decompressive surgery or treatment with anticoagulation alone. Studies show conflicting results, and there is scarce evidence regarding which strategy to prefer. Aim: To investigate whether early invasive treatment with thrombolysis and decompressive surgery in patients with PSVT, is associated with improved quality of life compared to delayed decompressive surgery or treatment with anticoagulation alone. Material and methods: Quality of life was evaluated in 87 patients treated for PSVT in Stockholm during 2008-2017. Treatment with immediate thrombolysis and surgery (acute group, n=46) was compared to treatment with delayed surgery (chronic group, n=20), and with anticoagulation alone (conservative group, n=21). The patients answered a disease-specific quality of life instrument (Disabilities of the arm, shoulder and hand, DASH) before and after intervention. One-way ANOVA and Post-hoc test was used to identify differences in DASH-score between the treatment groups. A multivariate regression model was used to adjust for potential confounders. Results: The acute group had superior outcome with lower DASH-score compared to the chronic group after intervention (p=.006), and compared to the chronic group and conservative group together (p=.0002). No confounders were found. Conclusions: Treatment of PSVT with immediate thrombolysis and surgery was related to superior results compared to delayed treatment. Because of the retrospective study design, more research is needed to clarify if causation is present.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Ethics Committe of Stockholm County (Regionala Etikprovningsnaemnden i Stockholm) gave ethical approval for this work (Diary number 2016/2484-31/2)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos